Recently, a new class of “living drugs” has been developed – Advanced Therapies which aim to transform the current focus of “treatment of disease” into one that concentrates on “restoration of health” with promising results in a broad field of Regenerative Medicine, including targeted immune reconstitution for cancer treatment. Advanced Therapies are game changing in Health Care and have a rapidly expanding market size of approximately 12 and 50 bn € expected by 2020 and 2030, respectively. There is great value in European science and technology on Advanced Therapies but Europe has been losing ground because of scattered and underpowered efforts. If Europe wants a leading role in this emerging field in the future, a mission-driven approach is required to make the transforming promise of Advanced Therapies a reality. The development of new Advanced Therapy products and their implementation in clinical practice will enhance the value-based outcome of patients. Measurable by having dozens of premier-league Advanced Therapy Products “discovered & made in Europa” by 2030 and beyond. Bringing affordable, standard-of-care for currently incurable diseases which are accessible for every European citizen who need it to RESTORE Health. We propose a mission-driven programme led by the candidate LSRI RESTORE, aiming to build a coordinated, financially strong European partnership between different areas of interest and cross-sectors involving academia, industry, regulatory authorities, health care, patient organisations, and public society. In order to guarantee a smart start of the LSRI from 2021 onwards, the preparation phase aims to involve the growing RESTORE community even more closely in working groups on identified tasks and to jointly complete the RESTORE agenda for Research & Innovation Actions as well as Coordination & Support Actions. The deliverables of RESTORE will allow Europe to gain a world leading health position within this emerging field.